LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Legal & Regulatory and Reimbursement/FDA Panel to Consider Reclassifying Spinal Spheres
Legal & Regulatory and Reimbursement

FDA Panel to Consider Reclassifying Spinal Spheres

November 12, 2013 1 min read Premium comments

Advertisement

FDA Panel to Consider Reclassifying Spinal Spheres
Advisory Committee / Source: FDA
Secondary

The FDA’s orthopedic expert panel will meet on December 12, 2013 to make recommendation regarding the classification of spinal sphere devices.

The devices are currently regulated under the heading of “Intervertebral Fusion Device with Bone Graft, Solid-Sphere, Lumbar”, Product Code NVR, as unclassified devices and reviewed under the 510(k) premarket notification authority. FDA is seeking committee input on the safety and effectiveness of spinal sphere devices and the regulatory classification for spinal sphere devices.

Since 2005, four manufacturers submitted 510(k) applications to clear their devices. They included Medtronic, Inc.’s Satellite Spinal System, Biomet Spine’s Spinal Stabilization Sphere System, Interbody Innovation LLP’s Spinal Spheres and PEEK Spinal Spheres and Life Spine’s Spinal Sphere System.

These devices are spheres manufactured from metallic (e.g., cobalt chromium molybdenum) or polymeric (e.g., polyetheretherketone) materials. According to the FDA, they are intended to be inserted between the vertebral bodies into the disc space from L3-S1 to help provide stabilization and to help promote intervertebral body fusion. During the arthrodesis procedure, they are to be used with bone graft for holding bone parts in alignment while they heal. These devices are not intended for use in motion-sparing, non-fusion procedures.

The Orthopaedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee will meet for two days at the Hilton Washington D.C. North, in Gaithersburg, Maryland. On December 13, the panel will consider reclassifying stair climbing wheelchairs from Class III to Class II.

To read the FDA announcement and participation details, click here.

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy